Artal Group S.A.'s Form 4 filing
Lexicon Pharmaceuticals, Inc.LXRX · filed Jun 5, 2023
- Accession no.
- 0000899243-23-014464
- Filed
- Jun 5, 2023, 4:46 PM ET
- Trade date
- Jun 5, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $72.2M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Artal Group S.A.CIK 0001053906 | Director, 10% Owner |
| Artal International S.C.A.CIK 0001218180 | Director, 10% Owner |
| Westend S.A.CIK 0001283968 | Director, 10% Owner |
| Invus Public Equities Advisors, LLCCIK 0001340096 | Director, 10% Owner |
| Invus Public Equities, L.P.CIK 0001340097 | Director, 10% Owner |
| Invus Advisors, L.L.C.CIK 0001404553 | Director, 10% Owner |
| Invus, L.P.CIK 0001404570 | Director, 10% Owner |
| Stichting Administratiekantoor WestendCIK 0001460840 | Director, 10% Owner |
| Artal International Management S.A.CIK 0001522131 | Director, 10% Owner |
| Wittouck AmauryCIK 0001841311 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2023 | Common Stock | PPurchaseAcquired | +27,775,050 | $2.60 | +$72,215,130 | 78,634,381 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Invus US Partners LLC directly holds 5,451,204 shares of Issuer Common Stock, which securities are reported on a separate Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.